Moreover, either knocking down EHMT2 expression or inhibiting EHMT2 activity resulted in increases in sensitivity to treatment with TKIs and decreases in cell migration and self-renewal ability in resistant NSCLC cells, suggesting that EHMT2 plays an important role in EGFR-TKI resistance in NSCLC (Fig. 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.